Adults with asthma treated with add-on Omalizumab report lower dyspnea in activities of daily living
J. Oliveira (Londrina, Brazil), D. Rugila (Londrina, Brazil), J. Silva (Londrina, Brazil), V. Puzzi (Londrina, Brazil), F. Pitta (Londrina, Brazil), A. Cerci Neto (Londrina, Brazil), F. Soares (Londrina, Brazil), K. Furlanetto (Londrina, Brazil)
Source: Virtual Congress 2021 – Respiratory physiotherapy: e-health, activities of daily living and measurement properties of instruments
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Oliveira (Londrina, Brazil), D. Rugila (Londrina, Brazil), J. Silva (Londrina, Brazil), V. Puzzi (Londrina, Brazil), F. Pitta (Londrina, Brazil), A. Cerci Neto (Londrina, Brazil), F. Soares (Londrina, Brazil), K. Furlanetto (Londrina, Brazil). Adults with asthma treated with add-on Omalizumab report lower dyspnea in activities of daily living. 764
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Evaluation of the relationship between the activity of daily living and dyspnoea in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 182s Year: 2005
Quality of life of patients with asthma exacerbations treated with high doses of inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 114s Year: 2002
A comparison of arm exercise capacity and activities of daily living between well-controlled asthma patients with and without severe fatigue during daily life Source: Virtual Congress 2021 – Peripheral muscle function, exercise capacity and functional status in respiratory disease Year: 2021
Tiotropium Respimat® add-on therapy in children with symptomatic asthma Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015
Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015
Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma Source: Eur Respir J, 55 (1) 1900964; 10.1183/13993003.00964-2019 Year: 2020
Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007
Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
LATE-BREAKING ABSTRACT: Once-daily tiotropium Respimat® add-on therapy improves lung function in children with moderate symptomatic asthma Source: International Congress 2016 – Living with asthma around the globe Year: 2016
Intermittent therapy with budesonide/formoterol in children with moderate asthma. Source: International Congress 2017 – Paediatric asthma: therapies and comorbidities Year: 2017
Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5 Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Reduction in percent of days with asthma symptoms and activity limitation in young asthmatic children treated with Montelukast Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001
Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities Source: Annual Congress 2012 - COPD treatment and varia Year: 2012
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Efficacy of montelukast in Indian patients having chronic persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003
Comparison of physical activity level, activities of daily living, and depression between the patients with asthma and bronchiectasis Source: International Congress 2017 – Assessing pulmonary and extra-pulmonary function in chronic disease Year: 2017
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007